Regeneron Pharmaceuticals (REGN) Interest Coverage Ratio (2009 - 2026)
Regeneron Pharmaceuticals (REGN) posted quarterly Interest Coverage Ratio of 24.64 for Q2 2026, down 76.72% year-over-year from 105.83 in Q2 2025, and up 8.46% quarter-over-quarter from 22.72 in Q1 2026.
Regeneron Pharmaceuticals (REGN) Interest Coverage Ratio (2009 - 2026) Analysis & Trends
Regeneron Pharmaceuticals' Interest Coverage Ratio history runs 18 years deep, the most recent figure standing at 24.64 for Q2 2026.
- In Q2 2026, Interest Coverage Ratio fell 76.72% year-over-year to 24.64; the TTM figure through Jun 2026 stood at 73.2 (down 80.56% YoY), while the FY2025 annual figure was 28.85, up 359.41% from the prior year.
- Interest Coverage Ratio for Q2 2026 stood at 24.64, up from 22.72 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 125.34 in Q4 2024, with the low at 3.53 in Q3 2022.
- The 5-year median for Interest Coverage Ratio is 23.68 (2026), against an average of 36.8.
- The sharpest annual moves came in 2022 and 2024: Interest Coverage Ratio plunged 98.31% in 2022, then surged 814.66% in 2024.
- Regeneron Pharmaceuticals' Interest Coverage Ratio stood at 65.91 in 2022, then dropped by 19.77% to 52.88 in 2023, then soared by 137.05% to 125.34 in 2024, then declined by 29.8% to 87.99 in 2025, then slumped by 72.0% to 24.64 in 2026.
- Business Quant data shows REGN's Interest Coverage Ratio at 24.64 in Q2 2026, 22.72 in Q1 2026, and 87.99 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.84 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 24.64 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -0.19 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.18 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.01 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.61 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 2.82 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.08 |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | -55.73 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.64 |
| Mar 31, 2026 | 22.72 |
| Dec 31, 2025 | 13.73 |
| Sep 30, 2025 | 53.20 |
| Jun 30, 2025 | 105.83 |
| Mar 31, 2025 | 33.43 |
| Dec 31, 2024 | 21.76 |
| Sep 30, 2024 | 45.37 |
| Jun 30, 2024 | 11.66 |
| Mar 31, 2024 | 7.18 |
| Dec 31, 2023 | 52.88 |
| Sep 30, 2023 | 4.96 |
| Jun 30, 2023 | 4.05 |
| Mar 31, 2023 | 3.94 |
| Dec 31, 2022 | 65.91 |
| Sep 30, 2022 | 3.53 |
| Jun 30, 2022 | 3.93 |
| Mar 31, 2022 | 5.82 |
| Dec 31, 2021 | 187.21 |
| Sep 30, 2021 | 130.08 |